BioLife Solutions, Inc.
NASDAQ:BLFSMedical - Instruments & Supplies
+$0.40 today
- Market cap
- $1.89B
- Beta
- 1.97
- P/E (TTM)
- -119.9
- EPS (TTM)
- -$0.22
Volume 4.39M
Average 0.52M
BLFS Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
BioLife Solutions, Inc.NASDAQ: BLFS
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin grows, but more slowly than its trailing trend
Q1 FY2026 selling, general & admin of $14.73M rose 4.5% year over year, behind the +20.2% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 17.5% from the prior quarter. Over 3 fiscal years it compounded at +7.2% a year.
Context
- Selling, general & admin amounted to 57.5% of revenue in FY2025, down 3.4 pp from a year earlier.
- Selling, general & admin increased in 2 of the last 3 fiscal years.
What to watch
Whether selling, general & admin reaches the consensus estimate from 4 analysts of $68.17M (+23.1%) for the fiscal year ending Dec 2026, a step up from the +10.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $14.73M+17.5% QoQ
- Last fiscal yearDec 2025
- $55.37M+10.4% YoY
- LTMMar 2026
- $56.01M+20.2% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 55.37M USD
- Year-over-year change
- +10.4%
- 4-year CAGR
- +3.6%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 55.37M | +10.4% |
| FY2024 | 2024-12-31 | 50.15M | -10.4% |
| FY2023 | 2023-12-31 | 55.97M | +24.6% |
| FY2022 | 2022-12-31 | 44.93M | -6.6% |
| FY2021 | 2021-12-31 | 48.09M | — |
Selling, General & Admin vs competitors
How BLFS compares with its peers on the latest reported figures
- BLFS's LTM Mar 2026 selling, general & admin of $56.01M is the 10th highest of the 11 companies compared; the peer median is $178.79M.
- Its year-over-year change of +20.2% is the 2nd highest of 10, against a peer median of -0.9%.
- Selling, general & admin amounts to 56.1% of revenue for BLFS, versus a peer median of 54.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $461.38M | +6.1% | +10.9% | 68.4% | |
| LTM Aug 2026 | $406.6M | -0.9% | +6.3% | 46.0% | |
| LTM Jun 2026 | $323.69M | +7.9% | +10.4% | 56.8% | |
| LTM Sep 2026 | $256.31M | +1.6% | -2.9% | 41.2% | |
| LTM Apr 2026 | $180.27M | -4.7% | -8.0% | 36.4% | |
| LTM Apr 2026 | $177.31M | -11.1% | +9.5% | 61.1% | |
| LTM Jan 2026 | $165.19M | +100.5% | — | 197.3% | |
| LTM Sep 2026 | $135.66M | -17.8% | +9.4% | 51.4% | |
| LTM Mar 2026 | $86.54M | — | — | 32.2% | |
| LTM Mar 2026 | $56.01M | +20.2% | +7.2% | 56.1% | |
| LTM Jun 2026 | $30.9M | -1.8% | +7.2% | 2607.6% | |
| Peer median (excluding BLFS) | $178.79M | -0.9% | +8.3% | 54.1% | |
Competitors are the stored peer set for BLFS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 119.16M | 76.24M | 75.86M | 82.25M | 96.21M |
| Cost of Revenue | 90.31M | 29.33M | 96.52M | 28.58M | 34.1M |
| Gross Profit | 28.85M | 46.91M | 46.75M | 53.67M | 62.12M |
| Gross Margin | 24.2% | 61.5% | 61.6% | 65.3% | 64.6% |
| Research & Development | 11.82M | 14.8M | 18.8M | 7.91M | 7.57M |
| Selling, General & Admin | 48.09M | 44.93M | 55.97M | 50.15M | 55.37M |
| Operating Expenses | 73.34M | 52.83M | 117.58M | 60.8M | 74.25M |
| Depreciation & Amortization | 12.87M | 19.96M | 12.3M | 8.66M | 4.69M |
| EBITDA | (16.65M) | (124.18M) | (45.24M) | 1.53M | 3.61M |
| EBITDA Margin | -14.0% | -162.9% | -59.6% | 1.9% | 3.7% |
| Operating Income | (35.16M) | (5.92M) | (23.44M) | (7.13M) | (1.08M) |
| Operating Margin | -29.5% | -7.8% | -30.9% | -8.7% | -1.1% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 485K | 687K | 1.81M | 719K | 2.71M |
| Other Income / Expenses | 6.13M | 1.08M | 4.97M | (4.3M) | (11M) |
| Income Before Tax | (29.03M) | (4.85M) | (18.47M) | (11.43M) | (12.08M) |
| Pre-Tax Margin | -24.4% | -6.4% | -24.4% | -13.9% | -12.6% |
| Income Tax Expense | (20.12M) | (5.24M) | 24K | (38K) | 49K |
| Net Income | (8.91M) | (139.81M) | (66.43M) | (20.18M) | (12.13M) |
| Net Margin | -7.5% | -183.4% | -87.6% | -24.5% | -12.6% |
| EPS (Basic) | (0.23) | (3.29) | (1.52) | (0.44) | (0.25) |
| EPS (Diluted) | (0.23) | (3.29) | (1.52) | (0.44) | (0.25) |
| Weighted Avg Shares | 38.5M | 42.48M | 43.72M | 46.07M | 47.75M |
| Weighted Avg Shares (Diluted) | 38.5M | 42.48M | 43.72M | 46.07M | 48.65M |
BioLife Solutions, Inc.
NASDAQ:BLFS
Intrinsic Alpha fair value
Locked
Current Price
$38.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.